📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-07-30 19:36
0 analysed today
0
Today
133,620
All-time analysed
40,132
Positive
6,284
Negative
79,384
Neutral
7,752
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
21 announcements match the current filters (relevance ≥ 5).
Epigral Q1 FY27: Revenue Up 15% to ₹709 Cr; Announces 125,000 TPA Epoxy Resin Expansion
Epigral reported a resilient Q1 FY27 with revenue growing 15% YoY to ₹709 Cr and adjusted PAT rising 25% to ₹99 Cr, despite logistical headwinds from the West Asia conflict. The company announced a major strategic forward integration into Epoxy Resins with a 125,000 TPA capacity, which will consume 50% of its in-house Epichlorohydrin (ECH) production. Management also highlighted that the Chlorotoluene value chain, including a new multipurpose plant, is expected to reach a top-line of ₹700-800 Cr at peak utilization. EBITDA margins saw a slight compression to 25% from 27% YoY due to volatile raw material costs.
Confidence: HIGH
What changedEpigral has transitioned from a specialty chemical producer to a forward-integrated Advanced Materials player by entering the Epoxy Resin segment.
Why it mattersThe move secures captive consumption for 50% of its ECH capacity and targets high-growth sectors like wind energy and electronics, strengthening its integrated manufacturing moat and reducing commodity cyclicality.
Q1 FY27 Revenue: ₹709 CrAdjusted PAT Growth (YoY): 25%New Epoxy Capacity: 125,000 TPAChlorotoluene Chain Revenue Potential: ₹700-800 CrNet Debt-to-EBITDA: 0.8xEBITDA Margin: 25%
📅 Short termThe stock may see positive sentiment following resilient earnings and a clear growth roadmap through high-value forward integration.
📈 Long termStructural growth is supported by doubling capacities in CPVC/ECH by H1 FY27 and the subsequent entry into Epoxy resins, potentially re-rating the business as a specialty materials player.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Volatility in raw material prices (Methanol, Gas) due to geopolitical conflicts
- Potential short-term oversupply in the domestic CPVC market
- Gestation period of 1.5-2 years for new plants to reach optimum utilization
Key Highlights
Q1 FY27 Revenue increased 15% YoY to ₹709 Cr, driven by volume growth and improved realizations.
Announced new 125,000 TPA Epoxy Resin & Formulations capacity to leverage integrated ECH and Caustic Soda production.
Chlorotoluene value chain revenue potential estimated at ₹700-800 Cr, up from the current base project potential of ₹300-350 Cr.
CPVC and ECH capacity doubling projects are on track for completion by H1 FY2027.
Net debt-to-EBITDA remains healthy at 0.8x as of June 30, 2026, despite ₹62 Cr capex spend in Q1.
👀 What to Watch
Watch for the commissioning of the pilot facility for Epoxy and MPP in Q2 FY27 to validate product quality. Monitor the ramp-up of the Chlorotoluene plant and the impact of methanol/gas price volatility on margins in upcoming quarters.
Epigral Q1 FY27: 15% Revenue Growth; Announces 125,000 TPA Epoxy Resin Expansion
Epigral reported a resilient Q1 FY27 with revenue growing 15% YoY to ₹709 cr and adjusted PAT rising 25% to ₹99 cr, despite logistical disruptions from the West Asia conflict. The company announced a major strategic entry into Epoxy Resins with a 125,000 TPA capacity, designed to consume 50% of its internal Epichlorohydrin (ECH) production. Management also detailed a new Multipurpose Plant (MPP) for specialty intermediates, with the combined Chlorotoluene and MPP value chain expected to generate ₹700-800 cr in annual revenue at peak. Existing projects to double CPVC and ECH capacities remain on track for H1 FY2027 completion.
Confidence: HIGH
What changedEpigral is transitioning from a merchant seller of ECH to a forward-integrated player in the Epoxy Resin and specialty chemical intermediates market.
Why it mattersThis shift reduces merchant market volatility and captures higher margins; the projected ₹700-800 cr revenue from the new value chain represents ~30% of current TTM revenue.
Q1 FY27 Revenue: ₹709 crNew Epoxy Capacity: 125,000 TPAProjected Value Chain Revenue: ₹700-800 crValue Chain Revenue vs TTM Revenue: ~28-32%EBITDA Margin: 25%Net Debt-to-EBITDA: 0.8x
📅 Short termThe stock may react positively to the expansion announcement and the management's ability to maintain 25% margins despite global supply chain headwinds.
📈 Long termThe structural shift toward high-value downstream derivatives (Epoxy, CPVC, MPP) is expected to drive double-digit growth and improve earnings quality through FY2027-28.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Volatility in raw material prices (Methanol and Gas) due to geopolitical conflicts
- Potential temporary overcapacity in the domestic CPVC market
- Execution risk for the large-scale Epoxy and MPP projects
Key Highlights
Revenue increased 15% YoY to ₹709 cr driven by higher volumes and realizations.
Announced new 125,000 TPA Epoxy Resin & Formulations capacity to facilitate forward integration.
Chlorotoluene and MPP value chain projected to reach ₹700-800 cr top line at peak utilization.
Adjusted PAT grew 25% YoY to ₹99 cr (excluding a ₹81 cr deferred tax adjustment in the base year).
Company plans to consume 50% of its expanded 100,000 TPA ECH capacity internally for Epoxy production.
👀 What to Watch
Watch for the commissioning of the pilot facility in Q2 FY27 and the progress of the CPVC/ECH capacity doubling by H1 FY2027, which are the primary near-term growth drivers.
Epigral Q1 FY27 PAT Rises 25% to ₹99 Cr; Board Approves 1.25 Lakh TPA Epoxy Resin Expansion
Epigral reported a strong Q1 FY27 with revenue growing 15% YoY to ₹709 Cr, supported by 5% volume growth and improved realizations. Adjusted PAT (excluding one-time tax benefits in the base year) rose 25% to ₹99 Cr, while EBITDA margins remained robust at 25%. The company announced a major strategic expansion into Epoxy Resins (1,25,000 TPA) and a Multi-Purpose Plant (MPP) for H2 FY28. Meanwhile, existing expansions in CPVC and ECH are on track for commissioning in Q2 FY27, which will double their respective capacities.
Confidence: HIGH
What changedEpigral has moved from the planning stage to board approval for a massive new specialty chemical value chain (Epoxy Resins) while maintaining strong double-digit earnings growth.
Why it mattersThe expansion into Epoxy Resins and MPP allows the company to consume its own raw materials (ECH and Caustic Soda), reducing commodity price risk and shifting the portfolio toward higher-margin specialty chemicals.
Q1 FY27 Revenue: ₹709 CrAdjusted PAT Growth (YoY): 25%New Epoxy Capacity: 1,25,000 TPANet Debt/EBITDA: 0.8xQ1 Revenue vs TTM Revenue: ~28%
📅 Short termThe stock may react positively to the earnings beat and the clarity provided on the next leg of growth through the Epoxy Resin capex.
📈 Long termStructural transformation from a Chlor-Alkali player to a diversified specialty chemical major is accelerating, which could lead to margin expansion and valuation re-rating over the next 2-3 years.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk for large-scale greenfield/brownfield projects
- Volatility in global freight costs and raw material prices
- Geopolitical tensions impacting export shipments
Key Highlights
Revenue increased 15% YoY to ₹709 Cr with overall plant utilization exceeding 80%
Adjusted PAT grew 25% to ₹99 Cr from ₹79 Cr in the previous year's corresponding quarter
Board approved a new 1,25,000 TPA Epoxy Resin & Formulations plant expected to commission by H2 FY28
CPVC capacity doubling to 1,50,000 TPA and ECH to 1,00,000 TPA remains on schedule for Q2 FY27
Net Debt/EBITDA maintained at a conservative 0.8x despite ongoing heavy capital expenditure
👀 What to Watch
Investors should monitor the successful commissioning and ramp-up of the CPVC and ECH expansions in Q2 FY27, as these are immediate growth drivers. The long-term focus remains on the execution of the newly announced Epoxy Resin project, which deepens vertical integration.
Epigral Q1 PAT Jumps 25% to ₹99 Cr; Announces ₹600 Cr Capex for Epoxy Resin & MPP
Epigral reported a strong Q1 FY27 with revenue growing 15% YoY to ₹709 Cr and PAT increasing 25% to ₹99 Cr. The company announced a major ₹600 Cr capex (approx. 24% of TTM revenue) to enter the Epoxy Resin business with a 1,25,000 TPA capacity and a Multi-Purpose Plant (MPP). This expansion is a strategic forward integration, as over 50% of raw material value will be sourced internally from existing ECH and Caustic Soda production. Commercial operations for the new plants are expected by H2 FY28, with a pilot plant starting as early as Q2 FY27.
Confidence: HIGH
What changedEpigral is transitioning from a Chlor-Alkali manufacturer into a high-value specialty chemicals player by entering the Epoxy Resin and Formulations market.
Why it mattersThe ₹600 Cr investment represents a significant 27% of the company's current net worth. By using captive raw materials for downstream products, Epigral aims to improve margins and reduce exposure to commodity price cycles.
Capex vs TTM Revenue: ~23.7%Q1 FY27 PAT Growth (YoY): 25%Planned Epoxy Capacity: 1,25,000 TPAEBITDA Margin: 25%Net Debt/EBITDA: 0.8xCapex Amount: ₹600 Cr
📅 Short termThe stock is likely to react positively to the double-digit earnings growth and the announcement of a large-scale, value-accretive expansion project.
📈 Long termThe entry into Epoxy Resins and MPPs could structurally re-rate the business by FY28, shifting the revenue mix toward high-margin specialty chemicals with strong domestic demand in renewables and electronics.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Project execution risk for the ₹600 Cr capex
- Volatility in global chemical prices
- Geopolitical tensions impacting freight costs and shipment timelines
Key Highlights
Q1 FY27 PAT increased 25% YoY to ₹99 Cr, up from ₹79 Cr in the previous year.
Approved ₹600 Cr capex for a 1,25,000 TPA Epoxy Resin plant and a Multi-Purpose Plant.
Revenue grew 15% YoY to ₹709 Cr, driven by 5% volume growth and improved realizations.
EBITDA margins remained healthy at 25%, with absolute EBITDA rising 10% to ₹179 Cr.
Net Debt/EBITDA maintained at a conservative 0.8x as of June 30, 2026.
👀 What to Watch
Watch for the commissioning of the pilot plant in Q2 FY27 and the timely execution of the larger ₹600 Cr project by H2 FY28. Additionally, monitor the ramp-up of the CPVC and ECH capacity doublings expected in H1 FY27.
Rs 600 Cr Capex: Epigral to Enter Epoxy Resin Segment with 1.25 Lakh TPA Facility
Epigral has announced a major strategic diversification into Epoxy Resins and a Multi-Purpose Plant (MPP) at its Dahej site with an investment of Rs 600 Cr. The proposed Epoxy Resin capacity is 1,25,000 TPA, with a targeted completion by H2 FY2028. This investment is significant, representing approximately 23.7% of the company's TTM revenue and 27% of its Net Worth. The project will be funded through a mix of debt and internal accruals, supported by a healthy current Debt/Equity ratio of 0.26.
Confidence: HIGH
What changedEpigral is officially diversifying into the Epoxy Resin value chain, moving further downstream from its core Chlor-Alkali and Chlorine derivative business.
Why it mattersThis move allows for better vertical integration by utilizing captive Epichlorohydrin (ECH) production. It shifts the revenue mix toward specialty chemicals, potentially reducing the impact of commodity price volatility in the Caustic Soda segment.
Total Investment: Rs 600 CrProposed Epoxy Capacity: 1,25,000 TPACapex vs TTM Revenue: ~23.7%Capex vs Net Worth: ~27.0%Target Completion: H2 FY2028
📅 Short termThe announcement is likely to be viewed positively by the market as it signals a clear growth path and value-addition strategy, though immediate earnings impact is nil.
📈 Long termThis is a structural shift towards becoming a more diversified specialty chemical player. Successful commissioning by FY2028 could significantly scale the top line and improve operating margins through integration.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk associated with large-scale greenfield/brownfield projects
- Potential increase in interest costs if debt component is high
- Market competition in the Epoxy Resin segment
Key Highlights
Total capital expenditure of Rs 600 Cr for new manufacturing lines
Proposed Epoxy Resin & Formulations capacity of 1,25,000 TPA
Projected completion timeline set for the second half of FY2028
Capex magnitude represents ~27% of the current Net Worth of Rs 2221 Cr
Expansion includes a Multi-Purpose Plant (MPP) to further diversify the product portfolio
👀 What to Watch
Monitor the execution timeline and the impact on the debt-to-equity ratio as the Rs 600 Cr capex is deployed. Investors should also track the commissioning of the ECH expansion in H1 FY2027, as ECH is a critical raw material for Epoxy Resins.
Epigral Q1 FY27: PBT Grows 25% YoY to ₹133.7 Cr; Finance Costs Drop 69%
Epigral reported a solid operational performance for Q1 FY27 with revenue growing 16.3% YoY to ₹705.36 Cr, despite a 4.2% sequential dip. Profit Before Tax (PBT) rose 25% YoY to ₹133.74 Cr, significantly aided by a 69% reduction in finance costs to ₹7.22 Cr. While reported PAT fell 38% YoY to ₹99.74 Cr, this is purely due to a high base in Q1 FY26 which included a one-time deferred tax credit of ₹80.87 Cr. The company also announced the incorporation of a new subsidiary, Epigral Advanced Material Limited, on July 7, 2026.
Confidence: HIGH
What changedRelease of Q1 FY27 financial results and the formation of a new subsidiary for advanced materials.
Why it mattersThe results demonstrate strong operational efficiency and significant deleveraging (lower interest costs), which helps offset the volatility in commodity chemical realizations.
Revenue (Q1 FY27): ₹705.36 CrRevenue vs TTM Revenue: ~27.9%PBT Growth (YoY): 24.98%Finance Cost Reduction (YoY): 69.1%One-time Tax Credit (Q1 FY26): ₹80.87 Cr
📅 Short termThe market is likely to view the strong PBT growth and interest cost savings positively, despite the optically lower YoY PAT caused by tax adjustments.
📈 Long termThe shift towards specialty derivatives and captive power generation supports a structural improvement in margins and reduces dependence on the cyclical Chlor-Alkali market.
⚠ Risk flags
- Volatility in Caustic Soda realizations
- Raw material price fluctuations
- Execution risk for the new advanced materials subsidiary
Key Highlights
Revenue from operations reached ₹705.36 Cr, up 16.3% from ₹606.54 Cr in the corresponding previous year quarter.
Finance costs saw a sharp reduction of 69.1%, falling to ₹7.22 Cr from ₹23.37 Cr in Q1 FY26.
Profit Before Tax (PBT) grew 22.1% sequentially to ₹133.74 Cr from ₹109.54 Cr in Q4 FY26.
The company incorporated a new wholly-owned subsidiary, Epigral Advanced Material Limited, on July 7, 2026, for chemical manufacturing.
Investing in a 19.80 MW Wind Solar Hybrid Power plant in Gujarat to optimize energy costs.
👀 What to Watch
Investors should monitor the ramp-up of the Chlorotoluene value chain and the commissioning of the 19.80 MW hybrid power plant to see if energy cost savings further boost margins.
Epigral Reaffirmed at CRISIL AA/Stable for Rs 1050 Crore Bank Facilities
CRISIL Ratings has reaffirmed Epigral Limited's long-term rating at 'CRISIL AA/Stable' and short-term rating at 'CRISIL A1+'. The rating covers total bank loan facilities of Rs 1050 crore, representing approximately 41.5% of the company's TTM revenue. This reaffirmation indicates a stable credit profile despite a 39.6% decline in share price over the last 12 months and a drop in plant utilization to 78% in Q2 FY2026. The company continues to focus on its expansion strategy, aiming to double CPVC and ECH capacities by H1 FY2027.
Confidence: HIGH
What changedCRISIL has completed its periodic review and maintained the existing credit ratings for Epigral's bank loan facilities without any upgrades or downgrades.
Why it mattersA stable 'AA' rating confirms the company's strong creditworthiness and ability to access capital at competitive rates, which is essential for its ongoing capital-intensive expansion into specialty chemical derivatives.
Total Bank Loan Facilities Rated: Rs 1050 CroreLong Term Rating: CRISIL AA/StableShort Term Rating: CRISIL A1+Rated Facilities vs TTM Revenue: 41.55%Current Debt: Rs 572 Cr
📅 Short termThe stock is likely to react neutrally as the rating reaffirmation was expected and represents no change in the company's fundamental credit risk profile.
📈 Long termThe maintenance of a high credit rating supports the company's long-term structural shift from commodity Chlor-Alkali to high-margin specialty derivatives, providing financial flexibility for future growth phases.
⚠ Risk flags
- Volatility in Caustic Soda realizations
- Decline in plant utilization (78% in Q2 FY2026 vs 83% in Q2 FY2025)
Key Highlights
Long-term credit rating reaffirmed at CRISIL AA/Stable for bank facilities.
Short-term credit rating reaffirmed at CRISIL A1+.
Total bank loan facilities covered under this rating amount to Rs 1050 crore.
Rating rationale was officially published by CRISIL on July 13, 2026.
Company maintains a low Debt-to-Equity ratio of 0.26 as per latest financial context.
👀 What to Watch
Monitor the execution and ramp-up of the CPVC and ECH capacity expansions scheduled for H1 FY2027, as these are critical for maintaining the 'Stable' outlook amidst volatile caustic soda realizations.
Epigral Limited 19th AGM: Final Dividend of ₹5.00 Per Share Approved
Epigral Limited conducted its 19th Annual General Meeting on June 08, 2026, where the management confirmed a final dividend of ₹5.00 per equity share for FY 2025-26. The Chairman highlighted the company's focus on capital expenditure and expansion plans to drive future growth in the multi-product chemical sector. Shareholders discussed the company's R&D initiatives and business performance in the context of the current geopolitical environment. Voting results for all six resolutions, including director re-appointments, will be finalized by June 10, 2026.
Key Highlights
Declared a final dividend of ₹5.00 (50%) per equity share of ₹10 each for FY 2025-26.
Management outlined strategic capital expenditure and expansion plans to sustain long-term growth.
Proposed the re-appointment of Mr. Ankit Patel and Mr. Karana Patel as Directors retiring by rotation.
Ratified M/s. S R B C & Co LLP as Statutory Auditors and M/s K V Melwani & Associates as Cost Auditors for FY 2026-27.
The meeting concluded with a positive outlook on the company's transition into a respected multi-product chemical entity.
👀 What to Watch
Investors should track the official voting results due by June 10, 2026, and monitor the execution of the mentioned capex plans which are key to future valuation.
Epigral Reaffirms CRISIL AA/Stable and A1+ Ratings for Rs 1050 Crore Bank Facilities
CRISIL Ratings has reaffirmed the credit ratings for Epigral Limited's bank loan facilities totaling Rs. 1,050 Crore. The long-term rating is maintained at 'CRISIL AA/Stable', while the short-term rating remains at 'CRISIL A1+', the highest possible rating for short-term instruments. This reaffirmation signifies the company's strong credit profile and its ability to meet financial obligations consistently. The stable outlook indicates that the company's credit risk profile is expected to remain steady in the medium term.
Key Highlights
CRISIL reaffirmed the Long Term Rating at 'CRISIL AA/Stable' for bank facilities.
CRISIL reaffirmed the Short Term Rating at 'CRISIL A1+' for bank facilities.
The ratings cover total bank loan facilities amounting to Rs. 1,050 Crore.
The reaffirmation reflects the company's sustained financial health and operational stability.
👀 What to Watch
Investors can take confidence in the company's high creditworthiness, which ensures access to low-cost capital and reflects strong management of debt obligations.
Epigral Shareholders Approve Re-appointment of Three Independent Directors for 5-Year Terms
Epigral Limited has announced the successful passage of three special resolutions via postal ballot for the re-appointment of Independent Directors Sanjay Asher, Kanubhai Patel, and Raju Swamy. All three directors have been appointed for a second term of five consecutive years starting May 20, 2026. While the resolutions passed with a requisite majority, there was notable dissent from public institutions regarding Mr. Asher and Mr. Swamy. The overall voter turnout stood at 66.59% of the total outstanding shares.
Key Highlights
Re-appointment of three Independent Directors for a second 5-year term effective May 20, 2026.
Mr. Kanubhai Patel received the highest approval with 99.98% of total votes in favor.
Mr. Sanjay Asher's re-appointment passed with 95.35% total favor, despite 55.52% institutional votes against.
Mr. Raju Swamy's re-appointment passed with 96.09% total favor, with 46.57% institutional votes against.
Total votes polled represented 28.73 million shares out of 43.14 million outstanding shares (66.59%).
👀 What to Watch
Investors should view this as a sign of leadership continuity and stability; however, the significant institutional dissent on two directors suggests a need to monitor future governance and board independence closely.
Epigral FY26 Revenue at ₹2,542 Cr; Dividend Record Date Set for June 1, 2026
Epigral Limited reported a flat revenue of ₹2,542 Cr for FY 2025-26, with EBITDA declining 20% to ₹567 Cr due to volatile raw material prices and lower utilization. The company's Net Profit stood at ₹333 Cr, which includes a one-time deferred tax benefit of ₹81 Cr. Despite margin pressure, the company maintained a healthy Net Debt/EBITDA of 0.9x and is proceeding with major expansions in CPVC and Epichlorohydrin. The Board has fixed June 1, 2026, as the record date for the FY26 dividend.
Key Highlights
Revenue stood at ₹2,542 Cr with EBITDA margins compressing from 28% to 22% YoY.
Net Profit of ₹333 Cr includes a ₹81 Cr tax benefit; adjusted PAT would be ₹252 Cr.
CPVC capacity expansion planned to double from 75,000 TPA to 150,000 TPA.
RoCE declined to 16% from 25% due to lower utilization and high capital work-in-progress.
Dividend record date fixed for June 01, 2026, with the AGM scheduled for June 08, 2026.
👀 What to Watch
Investors should focus on the commissioning timelines of the CPVC and ECH expansions which are critical for future growth. While short-term margins are under pressure, the low leverage and shift toward specialty derivatives provide long-term structural strength.
Epigral FY26 Revenue at ₹2,542 Cr; Plans Major CPVC Expansion to 150,000 TPA
Epigral reported a slight revenue decline of 1% to ₹2,542 Cr for FY 2025-26, while EBITDA fell 20% to ₹567 Cr due to higher raw material costs and compressed realizations. Despite the margin pressure, the company maintained a strong balance sheet with a Net Debt/EBITDA of 0.9x and a 17% increase in Net Worth to ₹2,221 Cr. The management is aggressively pursuing capacity-led expansion, including doubling CPVC resin capacity to 150,000 TPA and increasing bio-based Epichlorohydrin capacity to 100,000 TPA. A dividend for FY26 has been proposed with a record date of June 01, 2026.
Key Highlights
Revenue for FY26 stood at ₹2,542 Cr with a 10-year CAGR of 20%, despite a 1% YoY dip.
EBITDA margin compressed to 22% from 28% in the previous year due to volatile input costs.
Net Profit of ₹333 Cr includes a ₹81 Cr one-time deferred tax benefit; adjusted PAT stands at ₹252 Cr.
Proposed CPVC expansion from 75,000 TPA to 150,000 TPA to make Epigral one of the world's largest producers.
Maintained strong credit ratings of CRISIL AA/Stable and CRISIL A1+ with low leverage of 0.9x Net Debt/EBITDA.
👀 What to Watch
Investors should monitor the execution of the CPVC and ECH capacity expansions as they are critical for margin recovery and value diversification. The stock remains a long-term play on the shift from commodity Chlor-Alkali to high-value specialty derivatives.
Epigral FY26 Revenue at ₹2,542 Cr; Sets June 1 as Record Date for Dividend
Epigral Limited has scheduled its 19th AGM for June 8, 2026, and fixed June 1, 2026, as the record date for dividend entitlement. For FY 2025-26, the company reported a slight revenue dip of 1% to ₹2,542 crore, while EBITDA fell 20% to ₹567 crore due to higher raw material costs and compressed realizations. Despite the margin pressure, the company maintained a healthy Net Debt/EBITDA ratio of 0.9x and grew its net worth by 17% to ₹2,221 crore. Strategic focus remains on doubling CPVC capacity to 150,000 TPA and expanding the bio-based Epichlorohydrin capacity to 100,000 TPA.
Key Highlights
Revenue for FY26 stood at ₹2,542 crore, a marginal 1% decline YoY due to lower volumes and realizations.
EBITDA decreased by 20% to ₹567 crore with margins contracting to 22% from 28% in the previous year.
Company fixed June 1, 2026, as the record date for dividend payments and e-voting eligibility.
Major expansion underway to double CPVC resin capacity from 75,000 TPA to 150,000 TPA.
Net Debt/EBITDA remains robust at 0.9x, reflecting disciplined capital management despite sector headwinds.
👀 What to Watch
Investors should monitor the progress of the CPVC and ECH capacity expansions as they are key to future growth and margin recovery. The low leverage provides a safety margin during the current chemical sector slowdown.
Epigral Sets June 1, 2026, as Record Date for Final Dividend and 19th AGM
Epigral Limited has designated June 1, 2026, as the record date for its final dividend for the financial year 2025-26. The dividend is contingent upon shareholder approval at the company's 19th Annual General Meeting (AGM) scheduled for June 8, 2026. This date also serves as the cut-off for e-voting eligibility for the AGM proceedings. The announcement follows the completion of the fiscal year ending March 31, 2026.
Key Highlights
Record date for final dividend and AGM participation is fixed for June 1, 2026
19th Annual General Meeting (AGM) scheduled to be held on June 8, 2026
Dividend pertains to the financial year ended March 31, 2026
The AGM will be conducted through Video Conferencing (VC) or Other Audio Visual Means (OAVM)
👀 What to Watch
Investors interested in the dividend should ensure they hold the shares before the ex-dividend date. Monitor the AGM outcomes for the final approval of the dividend amount and management commentary.
Epigral Q4 FY26: PAT at ₹81.9 Cr, Recommends ₹5 Final Dividend
Epigral reported a revenue of ₹736.16 crore for Q4 FY26, representing a 17.3% growth year-on-year, although full-year revenue remained flat at ₹2,527.18 crore. Net profit for the quarter stood at ₹81.93 crore, a slight decline from ₹86.62 crore in the corresponding quarter of the previous year. The Board has recommended a final dividend of ₹5 per share, representing 50% of the face value. A significant jump in Capital Work in Progress to ₹450.83 crore indicates aggressive capacity expansion currently underway.
Key Highlights
Recommended a final dividend of ₹5.00 per equity share for the financial year 2025-26.
Q4 FY26 Revenue from operations grew to ₹736.16 Cr from ₹627.63 Cr in Q4 FY25.
Full-year FY26 Profit After Tax (PAT) decreased to ₹333.01 Cr compared to ₹356.70 Cr in FY25.
Capital Work in Progress (CWIP) surged to ₹450.83 Cr from ₹63.89 Cr, signaling major expansion projects.
Annual Earnings Per Share (EPS) for FY26 stood at ₹77.19, down from ₹84.45 in the previous year.
👀 What to Watch
Investors should focus on the execution and commissioning of the ₹450 crore expansion projects which are key to future revenue growth. While the dividend provides a steady return, the slight compression in annual margins suggests monitoring raw material and power costs.
Epigral Reports Record Q4 Revenue of ₹736 Cr, Up 17% YoY; Proposes ₹5 Dividend
Epigral delivered its highest-ever quarterly revenue of ₹736 crore in Q4FY26, marking a 17% YoY and 22% QoQ growth. While full-year FY26 revenue saw a marginal 1% dip to ₹2,542 crore, the company showed strong sequential recovery with PAT jumping 109% QoQ to ₹82 crore. The board has recommended a final dividend of ₹5 per share, reflecting confidence in the recovery. Significant capex of ₹394 crore was deployed during the year to double CPVC and Epichlorohydrin capacities, which are expected to drive future growth.
Key Highlights
Record Q4 revenue of ₹736 Cr (+17% YoY) and sequential PAT growth of 109% to ₹82 Cr
EBITDA margins improved significantly to 23% in Q4 from 17% in the previous quarter
Derivatives & Specialty business contribution increased to 54% of total revenue in Q4
Proposed final dividend of ₹5 per share (50% of face value) for FY2026
Ongoing capex to double CPVC capacity to 1,50,000 TPA and ECH capacity to 1,00,000 TPA
👀 What to Watch
Investors should note the strong sequential margin recovery and the shift towards high-margin specialty chemicals. The upcoming capacity expansions in CPVC and ECH are key triggers for growth in FY27.
Epigral Q4 FY26 PAT Jumps 109% QoQ to ₹82 Cr; Board Proposes ₹5 Dividend
Epigral reported a strong sequential recovery in Q4 FY26 with record quarterly revenue of ₹736 crore, up 22% QoQ, driven by 15% volume growth. While full-year FY26 revenue remained flat at ₹2,542 crore and EBITDA margins compressed to 22% from 28% YoY, the quarterly performance indicates a sharp rebound in utilization and demand. The company is aggressively expanding its high-margin Derivatives & Specialty segment, which now contributes 54% of Q4 revenue. Significant capex projects for CPVC and Epichlorohydrin are on track for H1FY27 commissioning, positioning the company for future growth.
Key Highlights
Q4 FY26 revenue reached a record ₹736 crore, growing 22% QoQ with plant utilization exceeding 80%.
Quarterly PAT surged 109% QoQ to ₹82 crore, while EBITDA margins improved to 23% from 17% in Q3.
Derivatives & Specialty segment contribution rose to 54% in Q4 FY26, highlighting a shift towards value-added products.
Board proposed a final dividend of ₹5 per share (50% of face value) for FY2026.
Major capacity expansions for CPVC (to 150 KTPA) and ECH (to 100 KTPA) are scheduled for commissioning in Q2 FY27.
👀 What to Watch
Investors should focus on the strong sequential recovery and the upcoming commissioning of world-class capacities in H1FY27. The shift towards specialty chemicals and manageable leverage (Net Debt/EBITDA of 0.9x) makes it a strong candidate for long-term growth portfolios.
Epigral Q4 Revenue Rises 17% to ₹736 Cr; Recommends ₹5 Dividend for FY26
Epigral Limited reported a strong 17.3% year-on-year growth in Q4 FY26 revenue, reaching ₹736.16 crore. However, the full-year net profit for FY26 saw a 6.6% decline to ₹333.01 crore, primarily due to higher finance costs and depreciation expenses. The company has recommended a final dividend of ₹5 per share (50% of face value). A significant jump in Capital Work in Progress to ₹450.83 crore indicates aggressive capacity expansion currently underway.
Key Highlights
Q4 FY26 revenue grew 17.3% YoY to ₹736.16 crore vs ₹627.63 crore in Q4 FY25.
Full-year FY26 Profit After Tax (PAT) decreased by 6.6% to ₹333.01 crore from ₹356.70 crore.
Board recommended a final dividend of ₹5.00 per equity share for the financial year 2025-26.
Capital Work in Progress (CWIP) surged to ₹450.83 crore from ₹63.89 crore, signaling major expansion.
Finance costs for the full year increased to ₹71.96 crore from ₹53.27 crore in the previous year.
👀 What to Watch
Investors should focus on the timeline for the commissioning of new projects represented by the high CWIP, which will be the primary driver for future earnings growth. The stock remains a steady play for long-term investors given the consistent dividend and ongoing expansion.
Epigral Q3 FY26: Revenue Grows 2% to ₹603 Cr; EBITDA Margins Contract to 17% Amid Cost Pressures
Epigral reported a marginal 2% sequential revenue growth to ₹603 crores in Q3 FY26, though EBITDA fell 22% to ₹103 crores due to lower realizations and higher raw material costs. The Derivatives and Specialty segment now contributes 52% of total revenue, aligning with the company's long-term target of 70%. Management highlighted a volume recovery starting mid-November 2025 and expects significant contributions from the chlorotoluene value chain starting FY27. Despite current margin pressure, the company maintains a healthy net debt to EBITDA ratio of 1.0x.
Key Highlights
Revenue grew 2% QoQ to ₹603 crores; EBITDA margins contracted to 17% from 22% in 9M FY26.
Derivatives and Specialty business contribution increased to 52% of total revenue.
Net debt remains stable at ₹557 crores with a comfortable Net Debt/EBITDA ratio of 1.0x.
Chlorotoluene value chain and CPVC capacity doubling on track for significant FY27 impact.
ECU realizations remained steady at approximately ₹29,000 to ₹30,000 per unit.
👀 What to Watch
Investors should monitor the recovery in realizations and the ramp-up of the chlorotoluene plant in FY27. The shift toward high-margin specialty derivatives provides a long-term cushion against commodity price volatility.
Epigral Q3 FY26 Revenue at ₹603 Cr; PAT Drops 62% YoY to ₹39 Cr Amid Margin Pressure
Epigral reported a weak Q3 FY26 with PAT falling 62% YoY to ₹39 Crore, primarily due to lower realizations and higher raw material costs. Revenue declined 7% YoY to ₹603 Crore, though it showed a marginal 2% sequential growth. EBITDA margins contracted significantly to 17% from 23% in the previous quarter. Despite short-term headwinds from an extended monsoon, management expects a recovery in Q4 FY26 and remains focused on its massive expansion projects in CPVC and Epichlorohydrin set for FY27.
Key Highlights
Revenue stood at ₹603 Cr, down 7% YoY but up 2% QoQ, with 52% contribution from Derivatives & Specialty segment.
PAT declined significantly to ₹39 Cr from ₹104 Cr in Q3FY25 and ₹51 Cr in Q2FY26.
EBITDA margins compressed to 17% due to softer product realizations and elevated input costs.
Net Debt increased to ₹557 Cr with a Net Debt/EBITDA ratio of 1.0x as of December 2025.
Major capex of ₹337 Cr spent in 9MFY26 on doubling CPVC and Epichlorohydrin capacities.
👀 What to Watch
Investors should monitor the recovery in realizations and margin stabilization in Q4 as guided by management. While current earnings are under pressure, the long-term growth depends on the successful commissioning of high-value specialty chemical capacities in FY27.
